(Q38059436)

28 August 2017

title

New treatments for IBS. (English)

1 reference

28 August 2017

2

Nicholas J Talley

1 reference

28 August 2017

Magnus Halland

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

13 November 2012

1 reference

Nature Reviews Gastroenterology & Hepatology

28 August 2017

published in

1 reference

28 August 2017

volume

10

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

13-23

1 reference

Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact.

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Irritable bowel syndrome in developing countries--a disorder of civilization or colonization?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A symptom-based approach to making a positive diagnosis of irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The impact of functional gastrointestinal disorders on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Suicidal ideation in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The economic consequences of irritable bowel syndrome: a US employer perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Irritable bowel syndrome: a technical review for practice guideline development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Differences between individuals with self-reported irritable bowel syndrome (IBS) and IBS-like symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Psychosocial factors at work and in every day life are associated with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Reports of "satisfactory relief" by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The irritable bowel syndrome: review and a graduated multicomponent treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The irritable bowel syndrome: long-term prognosis and the physician-patient interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Placebos without deception: a randomized controlled trial in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Investigating placebo effects in irritable bowel syndrome: a novel research design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Self-management for women with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A group-based patient education programme for high-anxiety patients with Crohn disease or ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The treatment of irritable bowel syndrome with hypnotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effects of gut-directed hypnotherapy on IBS in different clinical settings-results from two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Mood color choice helps to predict response to hypnotherapy in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Psychological treatments for irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Mindfulness training reduces the severity of irritable bowel syndrome in women: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Acupuncture for irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The multi-herbal drug STW 5 (Iberogast) has prosecretory action in the human intestine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Predictors of clinical response to gluten-free diet in patients diagnosed with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

HLA-DQ genotype is associated with accelerated small bowel transit in patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

21 January 2018

Exercise in fibromyalgia

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Outcome of biofeedback therapy in dyssynergic defecation patients with and without irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The utility of probiotics in the treatment of irritable bowel syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Meta-analysis of probiotics for the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A placebo-controlled trial of prucalopride for severe chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of linaclotide for patients with chronic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Rifaximin therapy for patients with irritable bowel syndrome without constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effects of rifaximin treatment and retreatment in nonconstipated IBS subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Pharmacological profile of ramosetron, a novel therapeutic agent for IBS

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

LX-1031, a tryptophan 5-hydroxylase inhibitor, and its potential in chronic diarrhea associated with increased serotonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Neurokinin-1-receptor antagonism decreases anxiety and emotional arousal circuit response to noxious visceral distension in women with irritable bowel syndrome: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Involvement of kappa-opioid receptors in visceral nociception in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of on-demand asimadoline, a peripheral kappa-opioid agonist, in females with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Bile acids and colonic motility in the rabbit and the human

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Pilot study: a randomised, double blind, placebo controlled trial of pancrealipase for the treatment of postprandial irritable bowel syndrome-diarrhoea

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Treatment of irritable bowel syndrome-diarrhea with pancrealipase or colesevelam and association with steatorrhea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Review article: new receptor targets for medical therapy in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Clinical trial: dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Atypical antipsychotic quetiapine in the management of severe refractory functional gastrointestinal disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Gabapentin reduces rectal mechanosensitivity and increases rectal compliance in patients with diarrhoea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Fecal microbiota transplantation and emerging applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Hypnotherapy for functional gastrointestinal disorders: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

IBS: Hypnotherapy--a wasted resource?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Lubiprostone: trials and tribulations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Organic and functional disorders in 2000 gastroenterology outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Presidential address: Gastrointestinal illness and the biopsychosocial model

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Controlled trial of hypnotherapy in the treatment of severe refractory irritable-bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Individual and group hypnotherapy in treatment of refractory irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Hypnosis treatment for severe irritable bowel syndrome: investigation of mechanism and effects on symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Internet-delivered exposure-based treatment vs. stress management for irritable bowel syndrome: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Herbal medicines for treatment of irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effects of an irritable bowel syndrome educational class on health-promoting behaviors and symptoms

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

The functional gastrointestinal disorders and the Rome III process

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Novartis suspends tegaserod sales at FDA's request

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effects of β-(1,3-1,6)-D-glucan on irritable bowel syndrome-related colonic hypersensitivity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2012.207

Effect of beta-glucan, inositol and digestive enzymes in GI symptoms of patients with IBS.

31 March 2020

1 reference

12 December 2020

Effect of a kappa-opioid agonist, i.v. JNJ-38488502, on sensation of colonic distensions in healthy male volunteers

1 reference

12 December 2020

The epidemiology of irritable bowel syndrome in North America: a systematic review

1 reference

12 December 2020

Symptomatology, quality of life and economic features of irritable bowel syndrome--the effect of hypnotherapy

1 reference

12 December 2020

Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?

1 reference

12 December 2020

Impairment in work productivity and health-related quality of life in patients with IBS.

1 reference

12 December 2020

Irritable bowel syndrome: toward a cost-effective management approach.

1 reference

12 December 2020

Evaluation of harm in the pharmacotherapy of irritable bowel syndrome

1 reference

12 December 2020

Do corticotropin releasing factor-1 receptors influence colonic transit and bowel function in women with irritable bowel syndrome?

1 reference

12 December 2020

Quality of life in managed care patients with irritable bowel syndrome

1 reference

12 December 2020

10.1038/NRGASTRO.2012.207

Identifiers

DOI

1 reference

28 August 2017

1 reference